|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Bisoprolol#Clinical Studies]] |
| {{Bisoprolol }}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Studies==
| |
| In two randomized double-blind placebo-controlled trials conducted in the U.S., reductions in systolic and diastolic blood pressure and heart rate 24 hours after dosing in patients with mild-to-moderate hypertension are shown below. In both studies, mean systolic/diastolic blood pressures at baseline were approximately 150/100 mm Hg, and mean heart rate was 76 bpm. Drug effect is calculated by subtracting the placebo effect from the overall change in blood pressure and heart rate.
| |
| {|
| |
| |-
| |
| |[[File:Betaxolol03.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| Blood pressure responses were seen within one week of treatment and changed little thereafter. They were sustained for 12 weeks and for over a year in studies of longer duration. Blood pressure returned to baseline when bisoprolol fumarate was tapered over two weeks in a long-term study.
| |
| | |
| Overall, significantly greater blood pressure reductions were observed on bisoprolol fumarate than on placebo regardless of race, age, or gender. There were no significant differences in response between black and nonblack patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZEBETA (BISOPROLOL FUMARATE) TABLET [DURAMED PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85 | publisher = | date = | accessdate = 4 February 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |